Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2019-11-06 Earnings Release
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
DiaSorin: 9 months 2019 results
Earnings Release Classification · 99% confidence The document text explicitly states the subject as "DiaSorin: 9 months 2019 results" and provides detailed consolidated economic and financial results for the first 9 months of 2019 (9M 2019) and the third quarter (Q3 2019). It includes key financial metrics like Revenues, EBITDA, EBIT, Net Profit, and Free Cash Flow, along with product development updates. This structure—a comprehensive financial review for a period shorter than a full year—is characteristic of an Interim/Quarterly Report. The document is substantial (over 32,000 characters) and contains the full results, not just a brief announcement of publication. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2019
2019-11-06 English
DiaSorin: risultati 9 mesi 2019
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for DiaSorin covering the first 9 months of 2019. It includes detailed financial statements (Revenue, EBITDA, EBIT, Net Income), segment analysis by geography and product line, and management commentary on performance. It is not a short announcement (it exceeds 35,000 characters) and contains substantive financial data, thus qualifying as an Interim/Quarterly Report rather than a mere announcement or regulatory filing. 9M 2019
2019-11-06 Italian
DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET
Regulatory Filings Classification · 98% confidence The document is an official communication from DiaSorin, dated October 30, 2019, announcing the FDA 510(k) clearance for a new diagnostic test (LIAISON® XL Zika Capture IgM II) for the US market. The header indicates it is 'Informazione Regolamentata' (Regulated Information) and the content is a press release detailing a product launch/regulatory milestone. This type of announcement, which is a specific business update rather than a comprehensive financial report (10-K, IR) or a general shareholder vote result, fits best under the category of a general Regulatory Filing or announcement that doesn't fit a more specific financial or governance code. Since it is a specific announcement of a regulatory/product milestone, and not a general earnings release (ER) or a capital change (CAP), it falls under the general regulatory announcement category, RNS, as it is a formal notification to the market about a significant operational/regulatory event.
2019-10-30 English
DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET
Regulatory Filings Classification · 95% confidence The document is a press release dated October 30, 2019, announcing that DiaSorin has received 510(k) clearance from the FDA for a new diagnostic test (LIAISON® XL Zika Capture IgM II) for commercial use in the US market. This is a specific announcement regarding a product/regulatory milestone, not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). It details a significant business development related to their product portfolio and market expansion. Since there is no specific category for 'Product/Regulatory Approval Announcement' outside of general regulatory filings, and it is not a standard financial report, it best fits the general 'Regulatory Filings' (RNS) category as a significant, non-financial regulatory update, or potentially a general 'Capital/Financing Update' (CAP) if the approval is viewed as a major business event, but RNS is the most appropriate fallback for specific regulatory news that isn't a core financial filing. Given the context of FDA clearance, RNS is the most suitable general regulatory announcement code.
2019-10-30 English
DIASORIN LANCIA IL TEST LIAISON® ZIKA CAPTURE IgM II NEL MERCATO STATUNITENSE PER IL RILEVAMENTO DELLE INFEZIONI DA VIRUS ZIKA
Regulatory Filings Classification · 95% confidence The document is a formal announcement dated October 30, 2019, from DiaSorin, detailing the receipt of 510(k) certification for commercializing the LIAISON® ZIKA Capture IgM II test in the US market. The structure, including the 'Oggetto' (Subject) field, the date, and the content announcing a specific business development (product launch/approval), strongly suggests a regulatory or general corporate announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific shareholder action (DIV, DVA), it falls best under the category of a general regulatory announcement or news release. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-financial, non-management-change corporate news that is being officially disseminated, especially when the text itself is an announcement ('Vedi allegato' - See attachment, though the attachment is not provided, the document acts as the primary announcement). It is not a proxy statement (PSI), director dealing (DIRS), or capital change (CAP). It is a specific business update, best categorized as RNS.
2019-10-30 Italian
DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET
Regulatory Filings Classification · 98% confidence The document is a formal announcement dated October 22, 2019, originating from DiaSorin, identified by the 'Informazione Regolamentata' header and the 'Oggetto' field stating 'DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET'. The text describes a product launch (FDA clearance for a diagnostic test) and includes commentary from the CEO. The document structure, metadata ('Tipologia: REGEM'), and content strongly suggest a regulatory disclosure of a significant business event, rather than a full financial report (10-K, IR) or a transcript (CT). Since it is a specific, material business announcement that doesn't fit perfectly into categories like M&A (TAR) or Capital Change (CAP), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but here it is a product/market update. Given the nature of a product launch announcement filed with a regulatory body (implied by the format), RNS is the most appropriate fallback for specific operational news not covered elsewhere. The document length (4339 chars) is moderate, but the content is a direct announcement, not a reference to an attached report, ruling out RPA.
2019-10-22 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.